The Icos Alumni: Where Are They Now?
Luke Timmerman11/18/09Comments (4)Follow @ldtimmerman
(Page 9 of 9)
—Liming Sui, pharmaceuticals professional
—Tom Swallow, consultant
—Jennifer Swank, analytical chemistry consultant, Swank Consulting
—Janelle Taylor, senior research associate II, VLST
—Elena Te, senior clinical design consultant, Phase Forward
—Sally Teeters, director of legal and business operations management, Calistoga Pharmaceuticals
—Bobbie Thomasson, senior research associate, Amgen
—Eugene Thorsett, pharmaceutical consultant
—James Tierney, accounting manager, Ste. Michelle Wine Estates
—Karen Tindall, director of clinical data management, Innovative Analytics [Added 12/30/09]
—Bill Tino, staff scientist, LigoCyte Pharmaceuticals
—Larry Tjoelker, senior director of research, Xori
—Carlos Toledano, vivarium manager, Benaroya Research Institute
—Nate Toy, manufacturing associate III, Bio-Rad Laboratories
—Sam Tran, senior associate scientist, Amgen
—Carol Tranfaglia, manager of clinical data management, Cell Therapeutics [Added: 9:41 pm, 9/7/10]
—Jennifer Treiberg, associate scientist II, Gilead Sciences
—Stephanie Tuck, preclinical scientist, Uptake Medical
—Brad Turcott, senior human resources manager, Seattle Genetics, director of human resources at Infospace
—Terry Turner, director of business development, PSI
—Stephanie Turner, biotechnology consultant
—Nancy Upton, executive assistant to the president and CFO, Genie Industries
—Linda Valentine, quality control analyst, ZymoGenetics
—Mike Van Brunt, scientist, Allozyne
—Mike Vandiver, director of pilot plant operations, Amgen
—Marie Rose van Schravendijk, associate director of analytical and formulation development, CMC Icos
—Rosemay Vazeux, scientist
—Joachim Veith, senior drug safety scientist, Genentech/Roche [Added 12/30/09]
—Satyanarayana Vunnam, scientist [Added 3/3/10]
—Andy Walker, associate director manufacturing technical operations, CMC Icos
—Susan Wang, strategic director for Asia, MDS Pharma Services
—Margie Watson, ambassador of first impressions, CMC Icos
—Steve Waugh, director of downstream process development, CMC Icos
—Dave Weber, security engineer, Network Computing Architects
—Joachim Weickmann, biotechnology professional
—Joe Weil, senior scientist, Trubion Pharmaceuticals
—Steven Whitaker, vice president of clinical development and chief medical officer, Allon Therapeutics
—Claire White, administrative specialist, ZymoGenetics
—Gary Wilcox, chairman and CEO, CoCrystal Discovery
—Pamela Wilkendorf, senior CMC project manager, CMC Icos
—Wendy Wisdom, senior associate scientist, Amgen
—Sharon Wolda, senior program manager, Intellectual Ventures
—Jeff Wood, associate director of global product development, PPD
—Michele (Koethe) Yetman, vice president of human resources, technology, Amazon.com
—Albert Yu, vice president, clinical affairs, chief medical officer, Calistoga Pharmaceuticals
—Patricia Zajac, executive coordinator, Gilead Sciences
—Kristin Ziegler, process development manager, CMC Icos
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Johnny T. Stine
11/18/09 1:48 pm
I actually loved our logo – very simple, but it just looked like fun.
When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.
By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)
Luke Timmerman
11/18/09 2:04 pm
Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.
I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?
David Miller
11/23/09 2:54 pm
Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.
Abby Kliphardt
3/3/10 10:19 am
Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….